Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...

Findings showed 77% of PV patients treated with rusfertide achieved a clinical response compared with 33% of those who received placebo. Topline data were announced from a phase 3 trial evaluating ...

Many people with polycythemia vera (PV) live a normal life with this rare blood cancer under control. The goal is to avoid complications like blood clots, which may happen because PV thickens your ...

Polycythemia vera (PV) is a slow-growing blood cancer in which your body makes too many red blood cells. You may have it for years before you notice any symptoms. Most people find out they have PV ...

A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line ...

Rusfertide showed a 77% clinical response rate in polycythemia vera patients, significantly higher than the 33% with placebo. The drug reduced phlebotomy frequency, with 0.5 per patient in the ...

The primary endpoint of the study was met, with a significantly higher proportion of clinical responders 1 among rusfertide-treated patients with PV (77%) compared to those who received placebo ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

“The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class ...

− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist ...